- Home
- SEIC vs BMRN Comparison
SEIC vs BMRN Comparison
Compare SEIC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEIC
- BMRN
- Stock Information
- Founded
- SEIC 1968
- BMRN 1996
- Country
- SEIC United States
- BMRN United States
- Employees
- SEIC N/A
- BMRN N/A
- Industry
- SEIC Investment Bankers/Brokers/Service
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SEIC Finance
- BMRN Health Care
- Exchange
- SEIC Nasdaq
- BMRN Nasdaq
- Market Cap
- SEIC 10.2B
- BMRN 9.9B
- IPO Year
- SEIC N/A
- BMRN 1999
- Fundamental
- Price
- SEIC $83.81
- BMRN $55.07
- Analyst Decision
- SEIC Buy
- BMRN Buy
- Analyst Count
- SEIC 7
- BMRN 19
- Target Price
- SEIC $100.29
- BMRN $90.26
- AVG Volume (30 Days)
- SEIC 639.8K
- BMRN 2.8M
- Earning Date
- SEIC 10-22-2025
- BMRN 10-27-2025
- Dividend Yield
- SEIC 1.17%
- BMRN N/A
- EPS Growth
- SEIC 30.71
- BMRN 59.53
- EPS
- SEIC 5.43
- BMRN 2.68
- Revenue
- SEIC $2,246,646,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- SEIC $9.87
- BMRN $13.32
- Revenue Next Year
- SEIC $8.01
- BMRN $7.51
- P/E Ratio
- SEIC $15.43
- BMRN $20.49
- Revenue Growth
- SEIC 9.44
- BMRN 12.39
- 52 Week Low
- SEIC $64.66
- BMRN $50.76
- 52 Week High
- SEIC $93.96
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- SEIC 56.29
- BMRN 57.93
- Support Level
- SEIC $80.59
- BMRN $50.76
- Resistance Level
- SEIC $82.84
- BMRN $53.49
- Average True Range (ATR)
- SEIC 1.35
- BMRN 1.87
- MACD
- SEIC 0.44
- BMRN 0.29
- Stochastic Oscillator
- SEIC 84.27
- BMRN 72.52
About SEIC SEI Investments Company
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $87 billion in assets under management. As of December 2024, SEI (including LSV) manages, administers, or advises about $1.6 trillion in assets.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.